Licensing failure in the European decentralised procedure

Area of Science:

• Pharmaceutical Sciences
• Regulatory Affairs
• Drug Development

Background:

• The European Union (EU) decentralized procedure is a primary route for marketing authorization applications.
• Limited data exists on licensing failures within the EU decentralized procedure compared to other regulatory pathways.
• Understanding licensing failure is crucial for optimizing drug approval processes.

Purpose of the Study:

• To determine the frequency of licensing failure for marketing authorization applications submitted via the EU decentralized procedure.
• To identify the key determinants and reasons behind licensing failures in this regulatory pathway.

Main Methods:

• Analysis of completed marketing authorization procedures between 2008 and 2012 where The Netherlands served as the leading authority.
• Assessment of licensing failures, including refusals and withdrawals.
• Categorization and evaluation of major objections cited in failed applications.

Main Results:

• A total of 492 procedures were completed, with 48 (9.8%) resulting in licensing failure (8 refusals, 40 withdrawals).
• A diverse range of major objections were identified, affecting both product quality (48 objections) and clinical aspects (45 objections).
• The overall low failure rate may be attributed to consistent communication between regulatory authorities and applicants.

Conclusions:

• The EU decentralized procedure demonstrates a relatively low rate of licensing failure.
• Quality and clinical issues represent significant, though not exclusive, reasons for application failure.
• Factors beyond regulatory objections, such as financial feasibility and applicant willingness to address concerns, influence withdrawal decisions.